Entrada Therapeutics Stock Performance

TRDA Stock  USD 10.88  0.08  0.74%   
On a scale of 0 to 100, Entrada Therapeutics holds a performance score of 9. The firm shows a Beta (market volatility) of 0.73, which means possible diversification benefits within a given portfolio. As returns on the market increase, Entrada Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Entrada Therapeutics is expected to be smaller as well. Please check Entrada Therapeutics' value at risk, kurtosis, market facilitation index, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Entrada Therapeutics' price patterns will revert.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Entrada Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent fundamental indicators, Entrada Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
0.74
Five Day Return
2.35
Year To Date Return
8.26
Ten Year Return
(54.57)
All Time Return
(54.57)
1
Acquisition by Baker Bros. Advisors Lp of 13386 shares of Entrada Therapeutics at 9.0688 subject to Rule 16b-3
11/24/2025
2
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635
12/04/2025
3
Entrada Therapeutics Navigating a Complex Investment Landscape - Ad-hoc-news.de
12/12/2025
4
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/17/2025
5
The Biggest IPO of the Year Prompts Huge Insider Buy
12/30/2025
6
Acquisition by Kim Peter S of 25000 shares of Entrada Therapeutics at 14.5869 subject to Rule 16b-3
01/02/2026
7
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
01/08/2026
8
Growth Report Will Entrada Therapeutics Inc benefit from rising consumer demand - Treasury Yields Real-Time Volume Trigger Notifications - baoquankhu1.vn
01/15/2026
9
Disposition of 1904 shares by Nathan Dowden of Entrada Therapeutics at 15.0684 subject to Rule 16b-3
01/27/2026
10
Entrada CEO Dipal Doshi to join biotech investor talks in New York, Boston - stocktitan.net
02/04/2026
11
Entrada Therapeutics, Inc. Given Consensus Recommendation of Hold by Brokerages - MarketBeat
02/10/2026
12
Does Entrada Therapeutics Impact Nasdaq Futures In Biotechnology
02/13/2026
Begin Period Cash Flow71.6 M
Total Cashflows From Investing Activities-27.8 M

Entrada Therapeutics Relative Risk vs. Return Landscape

If you would invest  882.00  in Entrada Therapeutics on November 18, 2025 and sell it today you would earn a total of  206.00  from holding Entrada Therapeutics or generate 23.36% return on investment over 90 days. Entrada Therapeutics is currently generating 0.4018% in daily expected returns and assumes 3.4204% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Entrada, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Entrada Therapeutics is expected to generate 4.53 times more return on investment than the market. However, the company is 4.53 times more volatile than its market benchmark. It trades about 0.12 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.16 per unit of risk.

Entrada Therapeutics Target Price Odds to finish over Current Price

The tendency of Entrada Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 10.88 90 days 10.88 
about 29.57
Based on a normal probability distribution, the odds of Entrada Therapeutics to move above the current price in 90 days from now is about 29.57 (This Entrada Therapeutics probability density function shows the probability of Entrada Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Entrada Therapeutics has a beta of 0.73. This usually implies as returns on the market go up, Entrada Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Entrada Therapeutics will be expected to be much smaller as well. Additionally Entrada Therapeutics has an alpha of 0.6248, implying that it can generate a 0.62 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Entrada Therapeutics Price Density   
       Price  

Predictive Modules for Entrada Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Entrada Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Entrada Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
7.4110.8414.27
Details
Intrinsic
Valuation
LowRealHigh
9.4112.8416.27
Details
4 Analysts
Consensus
LowTargetHigh
16.8418.5020.54
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-1.14-0.9-0.68
Details

Entrada Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Entrada Therapeutics is not an exception. The market had few large corrections towards the Entrada Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Entrada Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Entrada Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.62
β
Beta against Dow Jones0.73
σ
Overall volatility
0.95
Ir
Information ratio 0.17

Entrada Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Entrada Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Entrada Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Entrada Therapeutics had very high historical volatility over the last 90 days
Entrada Therapeutics currently holds about 244.25 M in cash with (41.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.81.
Over 77.0% of the company shares are owned by institutional investors
Latest headline from kalkinemedia.com: Does Entrada Therapeutics Impact Nasdaq Futures In Biotechnology

Entrada Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Entrada Stock often depends not only on the future outlook of the current and potential Entrada Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Entrada Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding39 M
Cash And Short Term Investments420 M

Entrada Therapeutics Fundamentals Growth

Entrada Stock prices reflect investors' perceptions of the future prospects and financial health of Entrada Therapeutics, and Entrada Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Entrada Stock performance.

About Entrada Therapeutics Performance

By analyzing Entrada Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Entrada Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Entrada Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Entrada Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.11  0.12 
Return On Capital Employed 0.09  0.09 
Return On Assets 0.11  0.12 
Return On Equity 0.15  0.18 

Things to note about Entrada Therapeutics performance evaluation

Checking the ongoing alerts about Entrada Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Entrada Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Entrada Therapeutics had very high historical volatility over the last 90 days
Entrada Therapeutics currently holds about 244.25 M in cash with (41.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.81.
Over 77.0% of the company shares are owned by institutional investors
Latest headline from kalkinemedia.com: Does Entrada Therapeutics Impact Nasdaq Futures In Biotechnology
Evaluating Entrada Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Entrada Therapeutics' stock performance include:
  • Analyzing Entrada Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Entrada Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Entrada Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Entrada Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Entrada Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Entrada Therapeutics' stock. These opinions can provide insight into Entrada Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Entrada Therapeutics' stock performance is not an exact science, and many factors can impact Entrada Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Entrada Stock analysis

When running Entrada Therapeutics' price analysis, check to measure Entrada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entrada Therapeutics is operating at the current time. Most of Entrada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Entrada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entrada Therapeutics' price. Additionally, you may evaluate how the addition of Entrada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings